Phage therapy in the era of synthetic biology

Cold Spring Harbor Perspectives in Biology

Volumn 8, Issue 10, 2016, Pages

  Barbu, E Magda ^a   Cady, Kyle C ^a   Hubby, Bolyn ^a  

^a Synthetic Genomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANIMAL; DEGENERATIVE DISEASE; HUMAN; MOUSE; NEOPLASM; PHAGE THERAPY; SYNTHETIC BIOLOGY;

ANIMALS; HUMANS; MICE; NEOPLASMS; NEURODEGENERATIVE DISEASES; PHAGE THERAPY; SYNTHETIC BIOLOGY; VACCINES;

EID: 84990840634     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a023879     Document Type: Article

References (117)

1. Abedon S. 2011. Phage therapy pharmacology: Calculating phage dosing. Adv Appl Microbiol 77: 1-40.
2. Alisky J, Iczkowski K, Rapoport A, Troitsky N. 1998. Bacteriophages show promise as antimicrobial agents. J Infect 36: 5-15.
3. Arias CA, Murray BE. 2009. Antibiotic-resistant bugs in the 21st century-A clinical super-challenge. N Engl J Med 360: 439-443.
4. Barrett ADT, Stanberry LR. 2008. Vaccines for biodefence and emerging and neglected diseases. Academic, Waltham, MA.
5. Barrow P, Lovell M, Berchieri A Jr. 1998. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diag Lab Immun 5: 294-298.
6. Baumann A. 2006. Early development of therapeutic biologics-Pharmacokinetics. Curr Drug Metab 7: 15-21.
7. Benhar I. 2001. Biotechnological applications of phage and cell display. Biotech Adv 19: 1-33.
8. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70: 204-210.
9. Boucher HW, Talbot GH, BenjaminDK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10 × '20 Progress-Development of new drugs active against Gramnegative bacilli: An update from the Infectious Diseases Society of America. Clin Infect Dis 56: 1685-1694.
10. Boyd EF, Brussow H. 2002. Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol 10: 521-529.
11. Bruttin A, Brussow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob Agents Chemother 49: 2874-2878.
12. Burdin N, Guy B, Moingeon P. 2004. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18: 79-93.
13. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. 2011. Bacteriophage therapy: Potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 9: 775-785.
14. Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzalez CF, Young RF, LiPuma JJ. 2010. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201: 264-271.
15. Carson L, Gorman SP, Gilmore BF. 2010. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 59: 447-455.
16. Carter CD, Parks A, Abuladze T, Li M, Woolston J, Magnone J, Senecal A, Kropinski AM, Sulakvelidze A. 2012. Bacteriophage cocktail significantly reduces Escherichia coli O157: H7 contamination of lettuce and beef, but does not protect against recontamination. Bacteriophage 2: 178-185.
17. Casadevall A, Pirofski LA. 2000. Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 68: 6511-6518.
18. Chanishvili N. 2012. Phage therapy-History from Twort and d’Herelle through Soviet experience to current approaches. Adv Vir Res 83: 3-40.
19. Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brussow H. 2004. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: Implications for phage therapy. Antimicrob Agents Chemother 48: 2558-2569.
20. Chiocca EA. 2002. Oncolytic viruses. Nat Rev Cancer 2: 938-950.
21. Clark JR, March JB. 2004a. Bacterial viruses as human vaccines? Exp Rev Vaccines 3: 463-476.
22. Clark JR, March JB. 2004b. Bacteriophage-mediated nucleic acid immunization. FEMS Immunol Med Microbiol 40: 21-26.
23. Clark JR, March JB. 2006. Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol 24: 212-218.
24. Curtin JJ, Donlan RM. 2006. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50: 1268-1275.
25. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201: 1096-1104.
26. DeLappe N, O’Halloran F, Fanning S, Corbett-Feeney G, Cheasty T, Cormican M. 2003. Antimicrobial resistance and genetic diversity of Shigella sonnei isolates fromwestern Ireland, an area of low incidence of infection. J Clin Microbiol 41: 1919-1924.
27. d’Herelle F. 1931. An address on bacteriophagy and recovery from infectious diseases. Can Med Assoc J 24: 619-628.
28. Eaton MD, Bayne-Jones S. 1934. Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 103: 1769-1776.
29. Enyeart PJ, Chirieleison SM, Dao MN, Perutka J, Quandt EM, Yao J, Whitt JT, Keatinge-Clay AT, Lambowitz AM, Ellington AD. 2013. Generalized bacterial genome editing using mobile group II introns and Cre-lox. Mol Syst Biol 9: 685.
30. Fairhead H. 2009. SASP gene delivery: A novel antibacterial approach. Drug News Perspect 22: 197-203.
31. Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L. 2005. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 23: 4860-4866.
32. Folkman J. 1997. Addressing tumor blood vessels. Nat Biotech 15: 510.
33. Frenkel D, Solomon B. 2002. Filamentous phage as vectormediated antibody delivery to the brain. Proc Natl Acad Sci 99: 5675-5679.
34. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54: 397-404.
35. Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, et al. 2012. Pseudomonas aeruginosa keratitis in mice: Effects of topical bacteriophage KPP12 administration. PloS ONE 7: e47742.
36. Furukawa H, Kuroiwa T, Mizushima S. 1983. DNA injection during bacteriophage T4 infection of Escherichia coli. J Bacteriol 154: 938-945.
37. Geier MR, Trigg ME, Merril CR. 1973. Fate of bacteriophage l in non-immune germ-free mice. Nature 246: 221-223.
38. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA III, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6: 343-345.
39. Goode D, Allen VM, Barrow PA. 2003. Reduction of experimental Salmonella and Campylobacter contamination of chicken skin by application of lytic bacteriophages. Appl Env Microbiol 69: 5032-5036.
40. Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M, Filby G. 2009. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 10: 766-774.
41. Górski A, Miedzybrodzki R, Borysowski J, Dabrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Lusiak-Szelachowska M, Klak M, et al. 2012. Phage as a modulator of immune responses: Practical implications for phage therapy. Adv Virus Res 83: 41-71.
42. GuJ, Liu X, Li Y, HanW, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, et al. 2012. A method for generation phage cocktail with great therapeutic potential. PloS ONE 7: e31698.
43. Gunther EJ, Murray NE, Glazer PM. 1993. High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage l DNA using a new E. coli lysogen. Nucleic Acids Res 21: 3903-3904.
44. Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U. 2004. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48: 3817-3822.
45. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd, Restel BH, Ozawa MG, Moya CA, Rangel R, et al. 2006. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125: 385-398.
46. Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM, Pasqualini R, Arap W. 2007. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protocols 2: 523-531.
47. Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, Soghomonyan S, Alauddin MM, Benjamin RS, Pollock RE, Gelovani JG, et al. 2008. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci 105: 4471-4476.
48. Hall AR, De Vos D, Friman VP, Pirnay JP, Buckling A. 2012. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Env Microbiol 78: 5646-5652.
49. HanlonGW. 2007. Bacteriophages: An appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30: 118-128.
50. Harper DR, Anderson J, Enright MC. 2011. Phage therapy: Delivering on the promise. Ther Deliv 2: 935-947.
51. Hatfull GF. 2008. Bacteriophage genomics. Curr Opin Microbiol 11: 447-453.
52. Hawkins C, Harper D, Burch D, Anggard E, Soothill J. 2010. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet Microbiol 146: 309-313.
53. Hendrix RW. 2003. Bacteriophage genomics. Curr Opin Microbiol 6: 506-511.
54. Ivanenkov V, Felici F, Menon AG. 1999. Uptake and intracellular fate of phage display vectors in mammalian cells. Biochem Biophys Acta 1448: 450-462.
55. Jaiswal A, Koley H, Ghosh A, Palit A, Sarkar B. 2013. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect 15: 152-156.
56. Jaschke PR, Lieberman EK, Rodriguez J, Sierra A, Endy D. 2012. A fully decompressed synthetic bacteriophage fX174 genome assembled and archived in yeast. Virology 434: 278-284.
57. Jiang J, Abu-Shilbayeh L, Rao VB. 1997. Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect Immun 65: 4770-4777.
58. Keen EC. 2012. Phage therapy: Concept to cure. Frontiers Microbiol 3: 238.
59. Kerr C, Sadowski PD. 1974. Packaging and maturation of DNA of bacteriophage T7 in vitro. Proc Natl Acad Sci 71: 3545-3549.
60. Kia A, Przystal JM, Nianiaris N, Mazarakis ND, Mintz PJ, Hajitou A. 2012. Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression. Mol Cancer Ther 11: 2566-2577.
61. Kingham R, Klasa G, Carver KH. 2014. Key regulatory guidelines for the development of biologics in the United States and Europe. In Biological drug products: Development and strategies, 1st ed. (ed. Wang Wand Singh M), pp. 75-109. Wiley, New York.
62. Kiro R, Shitrit D, Qimron U. 2014. Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol 11: 42-44.
63. Ksendzovsky A, Walbridge S, Saunders RC, Asthagiri AR, Heiss JD, Lonser RR. 2012. Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurgery 117: 197-203.
64. Kumari S, Harjai K, Chhibber S. 2009. Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae. J Microbiol Biotechnol 19: 622-628.
65. Kumari S, Harjai K, Chhibber S. 2010. Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products. J Infect Dev Ctries 4: 367-377.
66. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. 2010. Phage therapy in clinical practice: Treatment of human infections. Curr Pharmacol Biotechnol 11: 69-86.
67. Kutter E, Borysowski J, Miȩdzybrodzki R, Górski A, Weber-Dabrowska B, Kutateladze M, Alavidze Z, Goderdzishvili M, Adamia R. 2014. Clinical phage therapy. In Phage therapy: Current research and applications (ed. Borysowski J, et al.), pp. 257-288. Caister Academic, Norfolk, UK.
68. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8: 317-327.
69. Li XH, Tang L, Liu D, Sun HM, Zhou CC, Tan LS, Wang LP, Zhang PD, Zhang SQ. 2006. Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Chinese J Cancer 25: 1221-1226.
70. Lu TK, Collins JJ. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. ProcNatl Acad Sci 104: 11197-11202.
71. Lu TK, Koeris MS. 2011. The next generation of bacteriophage therapy. Curr Opin Microbiol 14: 524-531.
72. March JB, Clark JR, Jepson CD. 2004. Genetic immunisation against hepatitis B using whole bacteriophage l particles. Vaccine 22: 1666-1671.
73. Marinelli LJ, Piuri M, Swigonova Z, Balachandran A, Oldfield LM, van Kessel JC, Hatfull GF. 2008. BRED: A simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PloS ONE 3: e3957.
74. Martel B, Moineau S. 2014. CRISPR-Cas: An efficient tool for genome engineering of virulent bacteriophages. Nucleic Acids Res 42: 9504-9513.
75. Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP, Daly JM. 2005. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137: 639-646.
76. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, et al. 2003. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187: 613-624.
77. McVay CS, Velasquez M, Fralick JA. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51: 1934-1938.
78. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. 1996. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci 93: 3188-3192.
79. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2: 489-497.
80. Merril CR, Scholl D, Adhya S. 2006. Phage therapy. In The bacteriophages, 2nd ed. (ed. Calendar RL, Abedon S), pp. 725-741. Oxford University Press, London.
81. Neu HC. 1992. The crisis in antibiotic resistance. Science 257: 1064-1073.
82. Nobrega FL, Costa AR, Kluskens LD, Azeredo J. 2015. Revisiting phage therapy: New applications for old resources. Trends Microbiol 23: 185-191.
83. Ochs HD, Davis SD, Wedgwood RJ. 1971. Immunologic responses to bacteriophage fX 174 in immunodeficiency diseases. J Clin Invest 50: 2559-2568.
84. O’Flaherty S, Ross RP, MeaneyW, Fitzgerald GF, Elbreki MF, Coffey A. 2005. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl EnvMocrobiol 71: 1836-1842.
85. Ojala V, Laitalainen J, Jalasvuori M. 2013. Fight evolution with evolution: Plasmid-dependent phages with a wide host range prevent the spread of antibiotic resistance. Evol Appl 6: 925-932.
86. Oliveira A, Sereno R, Azeredo J. 2010. In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet Microbiol 146: 303-308.
87. Palmer KL, Gilmore MS. 2010. Multidrug-resistant enterococci lack CRISPR-cas. mBio 1: e00227.
88. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, et al. 2009. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNF a to cancer vasculature. PloS ONE 4: e4972.
89. Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82: 488-496.
90. Ptashne M. 2004. A genetic switch: Phage λ revisited. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
91. Rangel R, Guzman-Rojas L, le Roux LG, Staquicini FI, Hosoya H, Barbu EM, Ozawa MG, Nie KD Jr, Langley RR, et al. 2012. Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells. Nat Commun 3: 788.
92. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J Wound Care 18: 237-238, 240-233.
93. Rozema EA, Stephens TP, Bach SJ, Okine EK, Johnson RP, Stanford K, McAllister TA. 2009. Oral and rectal administration of bacteriophages for control of Escherichia coli O157: H7 in feedlot cattle. J Food Prot 72: 241-250.
94. Samson JE, Magadan AH, Sabri M, Moineau S. 2013. Revenge of the phages: Defeating bacterial defences. Nat Rev Microbiol 11: 675-687.
95. Sarker SA, McCallin S, Barretto C, Berger B, Pittet AC, Sultana S, Krause L, Huq S, Bibiloni R, Bruttin A, et al. 2012. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434: 222-232.
96. Shin J, Jardine P, Noireaux V. 2012. Genome replication, synthesis, and assembly of the bacteriophage T7 in a single cell-free reaction. ACS Synth Biol 1: 408-413.
97. Smith HO, Hutchison CA 3rd, Pfannkoch C, Venter JC. 2003. Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl Acad Sci 100: 15440-15445.
98. Soghomonyan S, Hajitou A, Rangel R, Trepel M, Pasqualini R, ArapW, Gelovani JG, Alauddin MM. 2007. Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU. Nat Protoc 2: 416-423.
99. Soni KA, Nannapaneni R. 2010. Bacteriophage significantly reduces Listeria monocytogenes on raw salmon fillet tissue. J Food Prot 73: 32-38.
100. Srinivasan S, Alexander JF, Driessen WH, Leonard F, Ye H, Liu X, Arap W, Pasqualini R, Ferrari M, Godin B. 2013. Bacteriophage associated silicon particles: Design and characterization of a novel theranostic vector with improved payload carrying potential. JMater Chem B Mater Biol Med 1: 5218-5229.
101. Stanford K, McAllister TA, Niu YD, Stephens TP, Mazzocco A, Waddell TE, Johnson RP. 2010. Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157: H7 in feedlot cattle. J Food Prot 73: 1304-1312.
102. Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG II, Liang X, Paolillo V, et al. 2011. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 121: 161-173.
103. Sulakvelidze A, Alavidze Z, MorrisJG Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659.
104. SummersWC. 2001. Bacteriophage therapy. Ann Rev Microbiol 55: 437-451.
105. Tandle A, Hanna E, LorangD, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, et al. 2009. Tumor vasculature-targeted delivery of tumor necrosis factor-α. Cancer 115: 128-139.
106. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H. 2005. Therapeutic use of phage cocktail for controlling Escherichia coli O157: H7 in gastrointestinal tract of mice. J Biosci Bioeng 100: 280-287.
107. Tetart F, Repoila F, Monod C, Krisch HM. 1996. Bacteriophage T4 host range is expanded by duplications of a small domain of the tail fiber adhesin. J Mol Biol 258: 726-731.
108. Tetart F, Desplats C, Krisch HM. 1998. Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: Recombination between conserved motifs swaps adhesin specificity. J Mol Biol 282: 543-556.
109. Tinsley CR, Bille E, Nassif X. 2006. Bacteriophages and pathogenicity: More than just providing a toxin? Microbes Infect 8: 1365-1371.
110. Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, ArapW, Hajitou A. 2009. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther 8: 2383-2391.
111. Twort FW. 1936. Further investigations on the nature of ultra-microscopic viruses and their cultivation. J Hygiene 36: 204-235.
112. Vitiello CL, Merril CR, Adhya S. 2005. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res 114: 101-103.
113. Wagenaar JA, Van Bergen MA, Mueller MA, Wassenaar TM, Carlton RM. 2005. Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet Microbiol 109: 275-283.
114. Wedgwood RJ, Ochs HD, Davis SD. 1975. The recognition and classification of immunodeficiency diseases with bacteriophage fX 174. Birth Defects Orig Artic Ser 11: 331-338.
115. Woolston J, Parks AR, Abuladze T, Anderson B, Li M, Carter C, Hanna LF, Heyse S, Charbonneau D, Sulakvelidze A. 2013. Bacteriophages lytic for rapidly reduce contamination on glass and stainless steel surfaces. Bacteriophage 3: e25697.
116. Wright A, Hawkins CH, Anggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34: 349-357.
117. Zanghi CN, Sapinoro R, Bradel-Tretheway B, Dewhurst S. 2007. Atractable method for simultaneous modifications to the head and tail of bacteriophage l and its application to enhancing phage-mediated gene delivery. Nucleic Acids Res 35: e59.